Roche's Avastin wins FDA green light in ovarian cancer

November 14, 2014 7:32 PM

11 0

Roche's ($RHHBY) Avastin is now two-for-two on converting recent FDA priority review designations into label expansions. Just three months after the cancer giant nabbed the agency's blessing for use in cervical cancer, regulators have approved the drug in combination with chemotherapy as a treatment for platinum-resistant, recurrent ovarian cancer.

The green light is based on data from the company's AURELIA study, which showed that Avastin cut the risk of the disease worsening by 62% in women who received it with chemotherapy.

Read more

To category page